Monoclonal Antibodies in the Treatment of Chronic Lymphoid Leukemias

References

• Kohler, G. and Milstein, C. (1975) "Continuous cultures of fused cells secreting antibody of predetined specificity", Nature, 256, 495–497.
   Google Scholar
• Dyer, M.J.S. (2001) "Historical aspects of the development of antibody therapy of B-cell malignancies." In Monoclonal Antibody Therapy of Hematologic Malignancies, edited by B.D. Cheson. Pp 1–12. Abingdon: Darwin Scientific Publishing Ltd.
   Google Scholar
• Robak, T. and Goldman, J.M. (1985) "Monoclonal antibodies reacting with myeloid cells", British Journal of Haematology, 61, 1–9.
   Google Scholar
• Kosmas, C., Stamatopoulos, K., Stavroyianni, N., Tsavaris, N. and Papadaki, T. (2002) "Anti-CD20 based therapy of B-cell lymphoma: state of the art", Leukemia, 16, 2004–2015.
   PubMed Web of Science ®Google Scholar
• O'Brien, S.M. Kantarjian, H., Thomas, D.A., Giles, F.J., Freireich, E.J., Cortes, J., et al. (2001) "Rituximab dose-escalation trial in chronic lymphocytic leukaemia", Journal of Clinical Oncology, 19, 2165–2170.
   PubMed Web of Science ®Google Scholar
• Huhn, D, von Schilling, C., Wilhelm, M., Hallek M., Kuse, R., Knauf, W., et al. (2001) "Rituximab therapy for patient with B-cell chronic lymphocytic leukaemia", Blood, 98, 1326— 1331.
   Google Scholar
• Keating, Mi., O'Brien, S. and Albitar, M. (2002) "Emerging information on the use of rituximab in chronic lymphocytic leukaemia", Seminars in Oncology, 29(1 suppl 2), 70–74.
   Google Scholar
• Osterborg, A., Dyer, M.J., Bunjes, D., Pangalis, G.A., Bastion, Y., Catovsky, D., et al. (1997) "Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leuke-mia", Journal of Clinical Oncology, 15, 1567 — 1574.
   Google Scholar
• Rai, KR., Freter, C.E., Mercier, R.J., Cooper, M.R., Mitchell, B.S., Stadtmauer, E.A., et al. (2002) "Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine", Journal of Clinical Oncology, 20, 3891 — 3897.
   Google Scholar
• Lundin, J., Kimby, E., Bjorkholm, M., Brolideu, P.A., Celsing, F., Hjalmar, V., et al. (2002) "Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)", Blood, 100, 768–773.
   PubMed Web of Science ®Google Scholar
• Keating, M.J., Flinn, I., JaM, V., Binet, J.L., Hillmen, P., Byrd, J., et al. (2002) "Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: result of a large international study", Blood, 99, 3554 — 3561.
   Google Scholar
• Onrust, S.V., Lamb, H.M. and Balfour J.A. (1999) "Rituximab", Drugs, 58, 79–88.
   PubMed Web of Science ®Google Scholar
• Maloney, G. (2001) "Mechanism of action of rituximab", Anti-Cancer Drugs, 12\(suppl 2), sl—s4.
   Google Scholar
• Hale, G. (2001) "The CD52 antigen and development of the CAMPATH antibodies", Cytotherapy, 3, 137— 143.
   Google Scholar
• Flynn, J.M. and Byrd, J.C. (2000) "Campath-1H monoclonal antibody therapy", Current Opinion in Oncology, 12, 574 — 581.
   Google Scholar
• Robbins, D.H., Margulies, I., Stetler-Stevenson, M. and Kreitman, R.J. (2000) "Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac (Fv)-P38 (LMB-2)", Clinical Cancer Research, 6, 693–700.
   PubMed Web of Science ®Google Scholar
• Kreitman, R.J., Wilson, W.H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., Fitzgerald, D.J., et al. (2001) "Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy resistant hairy cell leukemia", New England Journal of Medicine, 345, 241 — 247.
   Google Scholar
• Relf, M.E., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., et al. (1994) "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20", Blood, 83, 435–445.
   PubMed Web of Science ®Google Scholar
• Golay, I., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.M., Bernasconi, S., et al. (2000) "Biologic response of B lymphoma cells to anti- CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement- mediated cell lysis", Blood, 95, 3900— 3908.
   Google Scholar
• Cragg, M.S., Morgan, S.M., Chan, H.T., Morgan, B.P., Filatow, A.V., Johnson, P.W., et al. (2003) "Complement mediated lysis by anti-CD20 m Ab correlates with segregation into lipid rafts", Blood, 101, 1045 — 1052.
   Google Scholar
• Manches, O., Lui, G., Chaperot, L., Gressin, R., Molens, J.P., Jacob, M.C., et al. (2003) "In vitro mechanism of action of rituximab on primary non-Hodgkin lymphomas", Blood, 101, 949–954.
   PubMed Web of Science ®Google Scholar
• Shan, D., Ledbetter, J.A. and Press, O.W. (1998) "Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies", Blood, 91, 1644–1652.
   Google Scholar
• Shan, D., Ledbetter, J.A. and Press, O.W. (2000) "Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells", Cancer Immunology and Immunotherapy, 48, 673–683.
   PubMed Web of Science ®Google Scholar
• Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N. and Bonavida, B. (1997) "Chimeric anti-CD20 (IDEC-C2B8) mono-clonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs", Cancer Biotherapy and Radiopharmacsuticals, 12, 177 — 186.
   Google Scholar
• Chow, K.U., Sommerlad, W.D., Boehrer, S., Schneider, B., Seipelt, G., Rummel, M.J., et al. (2002) "Anti-CD20 antibody (IDEC-C238, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases", Haematologica, 87, 33–43.
   PubMed Web of Science ®Google Scholar
• Alas, S., Bonavida, B. and Emmanouilides, C. (2000) "Potentia-tion of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxyfilline and rituximab", Anticancer Research, 20, 2961 — 2966.
   Google Scholar
• Di Gaetano, N., Xiao, Y., Erba, E., Bassan, R., Rambaldi, A., Golay, J., et al. (2001) "Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line ressistant to the cytotoxic activity of either drug alone", British Journal of Haematology, 114, 800–809.
   Google Scholar
• Rummel, M.J., Chow, K.U., Hoelzer, D., Mitrou, P.S. and Weidmann, E. (2002) "In vitro studies with bendamustine: enhanced activity in combination with rituximab", Seminars in Oncology, 29(4 suppl 13), 12–14.
   PubMed Web of Science ®Google Scholar
• Rose, A.L., Smith, B.E. and Maloney, D.G. (2002) "Glucocorti-coids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects", Blood, 100, 1765— 1773.
   Google Scholar
• Shan, D., Gopal, A.K. and Press, O.W. (2001) "Synergistic effects of the fenretidine (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells", Clinical Cancer Research, 7, 2490–2495.
   PubMed Web of Science ®Google Scholar
• Smolewski, P., Szmigielska, A., Cebula, B., Sobczak, A., Dar-ynkiewicz, Z. and Robak, T. (2002) "Pro-apoptotic effect of rituximab alone and in combination with purine nucleoside analogues in B-cell chronic lymphocytic leukemia cells measared by fluorohrome labeled inhibitors of caspases (FIICA) assay", Blood, 100\(suppl 1), 387a.
   Google Scholar
• Hale, G., Bright, S., Chumbley, G., Hoang, T., Metcalf, D., Munro, A.J., et al. (1983) "Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement", Blood, 62, 873–883.
   Google Scholar
• Treumann, A., Lifely, M.R., Schneider, P. and Ferguson, M.A. (1995) "Primary structure of CD52", Journal of Biological Chemistry, 270, 6088–6099.
   PubMed Web of Science ®Google Scholar
• Smolewski, P., Darynldewicz, Z. and Robak, T. (2003) "Caspase-mediated cell death in hematological malignancies: theoretical considerations, methods of assessment and clinical implications", Leukemia and Lymphoma, 44, 1089 — 1104.
   Google Scholar
• Pangalis, G.A., Dimopoulou, M.N., Angelopoulou, M.K., Tse-kouras, C., Vassilakopoulos, T.P., Vaiopoulos, G., et al. (2001) "Campath-1H (anti CD52) monoclonal antibody therapy in lymphoproliferative disorders", Medical Oncology, 18, 99 — 107.
   Google Scholar
• Lundin, J., Osterborg, A., Brittingen, S., Crowther, D., Dombret, H., Engert, A., et al. (1998) "Campath-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lympho-mas: a phase II multicenter study", Journal of Clinical Oncology, 16, 3257 — 3263.
   PubMed Web of Science ®Google Scholar
• Kreitman, R.J., Wilson, W.H., Robbins, D., Margulies, I., Stetler-Stevenson, M., Waldmann, TA., et al. (1999) "Responses in refractory hairy cell leukemia to a recombinant immunotoxin", Blood, 94, 3340— 3348.
   Google Scholar
• Robbins, D.H., Margulies, I., Stetler-Stevenson, M. and Kreitman, R.J. (2000) "Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv) PE 38 (LMB-2)", Clinical Cancer Research, 6, 693–700.
   PubMed Web of Science ®Google Scholar
• Cordone, I., Annino, L., Masi, S.P., Pescarmona, E., Rahimi, S., Ferrari, A., et al. (1995) "Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia", Journal of Clinical Pathology, 48, 955–960.
   Google Scholar
• Salvatore, G., Beers, R., Margulies, I., Kreitman, R.J. and Pastan, I. (2002) "Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display", Clinical Cancer Research, 8, 995–1002.
   PubMed Web of Science ®Google Scholar
• Tedder, T.F., Tuscano, J., Sato, S. and Kehrl, J.H. (1997) "CD22, a B lymphocytic-specific adhesion molecule that regulates antigen receptor signalling", Annual Review of Immunology, 5, 481 — 504.
   Google Scholar
• Sausville, E.A., Headlee, D., Stetler-Stevenson, M., Jaffe, E.S., Solomon, D., Figg, W.D., et al. (1995) "Continuous infusion of the anti-CD22 immunotoxin IgG RFB4-SMPT-dgA in patients with B-cell lymphoma a phase I study", Blood, 85, 3457 — 3465.
   Google Scholar
• Brinkmann, U. (1996) "Recombinant immunotoxins protein engineering for cancer therapy", Molecular Medicine Today, 2, 439–446.
   Google Scholar
• Robbins, B.A., Ellison, DJ., Spinosa, J.C., Carey, CA., Lukes, R.J., Poppema, S., et al. (1993) "Diagnostic application of two color cytometry in 161 cases of hairy cell leukaemia", Blood, 82, 1277 —1287.
   Google Scholar
• Kreitman, R.J. (2003) "Immunological treatment of hairy- cell leukaemia", Best Practice and Research Clinical Haematology, 16, 117— 133.
   Google Scholar
• Nabhan, C., Dyer, M.J. and Rosen, S.T. (2003) "Current status of monoclonal antibody therapy for chronic lymphocytic leukaemia", Oncology (Huntinght) 17, 253–262
   PubMedGoogle Scholar
• Ginaldi, L., De Martins, M., Matutes, E., Fanahet, N., Monlle, R. and Catovsky, D. (1998) "Levels of expression of CD19 and CD20 in chronic B-cell leukaemia", Journal of Clinical Pathology, 51, 364–369.
   PubMed Web of Science ®Google Scholar
• Almasri, N.M., Duque, RE., Inturrapse, J., Everett, E. and Braylan, R.C. (1992) "Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukaemia", Amer-ican Journal of Hematology, 40, 259 — 263.
   Google Scholar
• Huh, Y.O., Keating, M.J., Saffer, H.L., Jilani, I., Lerner, S. and Albitar, M. (2001) "Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukaemia", American Journal of Clinical Pathology, 116, 437–434.
   PubMed Web of Science ®Google Scholar
• Nabhan, C. and Rosen, S.T. (2002) "Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukaemia", Seminars in Oncology, 29(1 suppl 2), 75 — 80.
   Google Scholar
• Petryk, M., and Grossbard, M.L. (2000) "Rituximab therapy of B-cell neoplasms", Clinical Lymphoma, 1, 186 — 194.
   Google Scholar
• Manshouri, T., Do, K.A., Wang, X., Giles, F.J., O'Brien, S.M., Safer, H., et al. (2003) "Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and its prognostic significance", Blood, 101, 2507 — 2513.
   Google Scholar
• Rossmann, E.D., Lundin, J., Lenkei, R., Mellstedt, H. and Osterborg, A. (2001) "Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies", The Hematology Journal, 2, 300— 306.
   Google Scholar
• McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czucz-man, M.S., Williams, M.E., et al. (1998) "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lym-phoma: half of patients responded to a four-dose treatment program", Journal of Clinical Oncology, 16, 2825–2833.
   PubMed Web of Science ®Google Scholar
• Byrd, J.C., Murphy, T., Howard, R.S., Lucas, M.S., Goodrich, A., Park, K., et al. (2001) "Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and accep-table toxicity", Journal of Clinical Oncology, 19, 2153— 2164.
   Google Scholar
• Herold, M., Schulze, A., Hartwig, K. and Anger, G. (2000) "Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD20 antibody rituximab", Annals of Hematology, 79, 332–335.
   PubMed Web of Science ®Google Scholar
• Itala, M., Geisler, CH., Kimby, E., Juvonen, E., Tjonnfjord, G., Karlson, K. and Remes, K (2002) "Standard dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukemia: results from a Nordic multicentre study", European Journal of Haematology, 69, 129 — 134.
   Google Scholar
• Schulz, H., Klein, S.K., Rehwald, U., Reiser, M., Hinke, A., Knauf, W.U., et al. (2002) "Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukaemia", Blood, 100, 3115 — 3120.
   Google Scholar
• Savage, D.G., Cohen, N.S., Hesdorffer, CS., Heitjan, D., Oster, M.W., Garrett, T.J., et al. (2003) "Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukaemia", Leukemia and Lymphoma, 44, 477–481.
   PubMed Web of Science ®Google Scholar
• Byrd, J.C., Peterson, B.L., Morrison, V.A., Park, K., Jacobson, R., Hoke, E., et al. (2003) "Randomized phase 2 study of fludarabine with concurrent vs. sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALG B9712)", Blood, 101, 6–14.
   Google Scholar
• Byrd, J.C., Lucas, M., Cheson, B.D. and Flinn, I.W. (2002) "Monoclonal antibody therapies for patients with chronic lymphocytic leukaemia". In: Monoclonal Antibody Therapy of Hematologic Malignancies, edited by B.D. Cheson. Pp 91–112. Abingdon, Oxfordshire: Darwin Scientific Publishing Ltd.
   Google Scholar
• Manshouri, T., Saffer, H., Keating, M. and Albitar, M. (2000) "Clinical relevance of circulating CD20 in patients with chronic lymphocytic leukaemia", Blood, 96\(suppl 1), 369a (abstract).
   Google Scholar
• Byrd, J.C., Smith, L., Hackbarth, M.L., Flinn, I.W., Young, D., Proffitt, J.H., et al. (2003) "Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab", Cancer Research, 63, 36— 38.
   Google Scholar
• Di Gaetano, N., Xiao, Y., Erba, E., Bassan, R., Rambaldi, A., Golay, J., et al. (2001) "Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone", British Journal of Haematology, 114, 800–809.
   Google Scholar
• Alas, S., Bonavida, B. and Emmanouilides, C. (2000) "Potentia-tion of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifyline and rituximab", Anticancer Research, 20, 2961 — 2966.
   Google Scholar
• Alas, S., Emmanouilides, C. and Bonavida, B. (2001) "Inhibition of interleukin 10 by rituximab results in down regulation of bc1-2 and sensitization of B-cell non-Hodgkin's lymphoma to apopto-sis", Clinical Cancer Research, 7, 709–723.
   PubMed Web of Science ®Google Scholar
• Wierda, W., O'Brien, S., Albitar, M., Lerner, S., Phunkett, W., Giles, F., et al. (2001) "Combined fludarabine, cyclophosphamide and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia (abstract)", Blood, 98, 771a. (Abstract 3210).
   Google Scholar
• Lee, E., Zamkoff, K. and Gentile, T. (2000) "Rituxan in the treatment of auto-immune hemolytic anemia", Blood, 96(suppl la), 596a (abstract ).
   Google Scholar
• Zecca, M., DiStefano, P., Mobili, B. and Locatelli, F. (2001) "Anti-CD20 monoclonal antibody for the treatment of severe immune-mediated, pure red cell aplasia and hemolytic anemia", Blood, 97, 3995 — 3997.
   Google Scholar
• Stasi, R., Pagano, A., Stipa, E. and Amadori, S. (2001) "Rituximab chimeric anti CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura", Blood, 98, 952–957.
   PubMed Web of Science ®Google Scholar
• Berentsen, S., Tjonnfjord, G.E., Brudevold, R., Gjertsen, B.T., Langholm, R., Lokkevik, E., et al. (2001) "Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease", British Journal of Haematology, 115, 79–83.
   PubMed Web of Science ®Google Scholar
• Gupta, N., Kavuru, S., Patel, D., Janson, D., Driscoll, N., Ahmed, S., et al. (2002) "Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukaemia", Leukemia, 16, 2092–2095.
   Google Scholar
• Iannitto, E., Ammatuna, E., Marino, C., Cirrincione, S., Greco, G. and Mariani, G. (2002) "Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolitic anemia to anti-CD20 monoclonal antibody", Blood, 99, 1096 — 1097.
   Google Scholar
• Ghazal, H. (2002) "Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukaemia", Blood, 99, 1092–1094.
   Google Scholar
• Marotta, G., Lenoci, M., Fabbri, A., Tozzi, M. and Lauria, F. (2002) "Efficacy of rituximab in the treatment of refractory chronic lymphocytic leukemia patient with bone marrow aplasia", The Hematology Journal, 3, 299 — 301.
   Google Scholar
• Hegde, UT., Wilson, W.H., White, T. and Cheson, B.D. (2002) "Rituximab treatment of refractory fludarabine-associated im-mune thrombocytopenia in chronic lymphocytic leukaemia", Blood, 100, 2260–2262.
   Google Scholar
• Seipelt, G., Bohme, A., Koschmieder, S. and Hoelzer, D. (2001) "Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome", Annals of Hematology, 80, 170— 173.
   Google Scholar
• McCune, S.L., Gockerman, J.P., Moore, J.0., Decastro, CM., Bass, A.J., Chao, N.J., et al. (2002) "Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukaemia", Leukemia and Lymphoma, 43, 1007–1011.
   PubMed Web of Science ®Google Scholar
• Pangalis, G.A., Dinopoutou, M.N., Angelopoulou, M.K., Tse-kouras, C.H. and Siakantaris, M.P. (2000) "Campath-1H in B-chronic lymphocytic leukemia: report on a patient treated thrice in a 3 year period", Medical Oncology, 17, 70–73.
   Google Scholar
• Montillo, M., Cafro, AM., Tedeschi, A., Brando, B., Oreste, P., Veronese, S., et al. (2002) "Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine", Haematologica, 87, 695–700.
   PubMed Web of Science ®Google Scholar
• Kennedy, B., Rawstron, A., Carter, C., Ryan, M., Speed, K., Lucas, G., et al. (2002) "Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukaemia", Blood, 99, 2245–2247.
   PubMed Web of Science ®Google Scholar
• Nabhan, C. and Rozeu, S.T. (2002) "Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukaemia", Seminars in Oncology, 29\(suppl 2), 75 — 80.
   Google Scholar
• Osterborg, A., Fassas, AS., Anagnostopoulos, A., Dyer, M.J., Catovsky, D. and Mellstedt, H. (1996) "Humanized CD52 monoclonal antibody Campath-1H as first line treatment in chronic lymphocytic leukaemia", British Journal of Haematology, 93, 151–153.
   PubMed Web of Science ®Google Scholar
• Dyer, M.J., Kelsey, S.M., Mackay, H.J., Emmett, E., Thornton, P., Hale, G., et al. (1997) "In vivo "purging" of residual disease in CLL with Campath-1H", British Journal of Haematology, 97, 669 — 672.
   Google Scholar
• Nabhan, C., Tallman, M.S., Riley, M.B., Fitzpatrick, J., Gordon, L.I., Gartenhaus, R., et al. (2001) "Phase I study of combining rituximab and Campath-1H in patients with relapsed or refractory chronic lymphocytic leukaemia", Blood, 98(suppl la), 365a (abstract 1536).
   Google Scholar
• Faderi, S., Thomas, D.A., O'Brien, S., Garcia-Manero, G., Kantarjian, H.M., Giles, F.J., et al. (2003) "Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies", Blood, 101, 3413–3415.
   PubMed Web of Science ®Google Scholar
• Bowen, A.L., Zomas, A., Emmett, E., Matutes, E., Dyer, M.J. and Catovsky, D. (1997) "Subcutaneous CAMPATH-1H in fludar-abine-resistant/relapsed chronic lymphocytic and B-prolymphocy-tic leukaemia", British Journal of Haematology, 96, 617 — 619.
   Google Scholar
• Hale, G., Slavin, S., Goldman, J.M., Mackinnon, S., Giralt, S. and Waldmann, H. (2002) "Alemtuzumab (Campath-1H) for treat-ment of lymphoid malignancies in the age of nonmyeloablative conditioning", Bone Marrow Transplantation, 30, 797–804.
   PubMed Web of Science ®Google Scholar
• Hale, G., Cobbold, S., Novitzky, N., Bunjes, D., Willemze, R., Prentice, H.G., et al. (2001) "CAMPATH-1 antibodies in stem-cell transplantation", Cytotherapy, 3, 145–164.
   PubMed Web of Science ®Google Scholar
• Dyer, M.J.S., Kelsey, S.M., Mackay, H.J., Emmett, E., Thornton, P., Hale, G., et al. (1997) "In vivo purging of residual CLL with Campath-1H", British Journal of Haematology, 97, 669–672.
   PubMed Web of Science ®Google Scholar
• Lush, R.J., Haynes, A.P., Byrne, J.L., Cull, G.M., Carter, G.I., Pagliuca, A., et al. (2001) "Allogenic stem-cell transplantation for lymphoproliferative disorders using BE AM — CAMPATH (± fludarabine) conditioning combined with post-transplant donor lymphocyte infusion", Cytotherapy, 3, 210–208.
   Google Scholar
• Kennedy, B., Rawstron, A.C., Evans, P., English, A., Haynes, A.P., Russell, N.H., et al. (1999) "Compath-1H therapy in 29 patients with refractory CLL: "true" complete remission is an attainable goal", Blood, 94\(suppl 1), 603a (Abstr 2683).
   Google Scholar
• Kottaridis, P.D., Milligan, D.W., Chopra, R., Chakraverty, R.K., Chakrabarti, S., Robinson, S., et al. (2000) "In vivo CAMPATH-1H prevents graft vs. host disease following nonmyeloablative stem cell transplantation", Blood, 96, 2419 — 2425.
   Google Scholar
• Matutes, E., Brito-Babapulle, V., Dearden, C., Yullie, M.R. and Catovsky, D. (2001) "Prolymphocytic leukemia of B- and T-cell types. Biology and therapy". In Chronic Lymphoid Leukemias. Edited by B.D. Cheson. Pp 525–541. New York Basel: Marcell Dekkeker, Inc.
   Google Scholar
• Pawson, R., Dyer, M.J.S., Barge, R., Matutes, E., Thornton, P.D., Emmett, E., et al. (1997) "Treatment of T-cell prolymphocytic leukemia with human CD52 antibody", Journal of Clinical Oncology, 15, 2667 — 2672.
   Google Scholar
• Ginaldi, L., De Martinis, M., Matutes, E., Farahat, N., Morilla, R., Dyer, M.J.S., et al. (1998) "Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H", Leukemia Research, 22, 185–191.
   Google Scholar
• Dearden, C.E., Matutes, E., Cazin, B., Tjonnfjord, G.E., Parreira, A., Nomdedeu, B., et al. (2001) "High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H", Blood, 98, 1721— 1726.
   Web of Science ®Google Scholar
• Keating, M.J., Cazin, B., Coutre, S., Birhiray, R., Kovacsovics, T., Langer, W., et al. (2002) "Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed", Journal of Clinical Oncology, 20, 205–213.
   PubMed Web of Science ®Google Scholar
• Perz, J., Topaly, J., Fruehauf, S., Hensel, M. and Ho A.D. (2002) "Level of CD20 expression and efficacy of rituximab treatment of patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukaemia", Leukemia and Lymphoma, 43, 149 — 151.
   Google Scholar
• Allsup, D.J. and Cawley, J.C. (2002) "The diagnosis and treatment of hairy-cell leukaemia", Blood Reviews, 16, 255–262.
   Google Scholar
• Lauria, F., Lenoci, M., Amino, L., Raspadori, D., Marotta, G., Bocchia, M., et al. (2001) "Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukaemia", Haematologica, 86, 1046–1050.
   PubMed Web of Science ®Google Scholar
• Hagberg, H. and Lundholm, L. (2001) "Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia", British Journal of Haematology, 115, 609 — 611.
   Google Scholar
• Pollio, F., Pocali, B., Palmieri, S., Morabito, P., Scalia, G., Del Vecchio, L., et al. (2002) "Rituximab a useful drug for a repeatedly relapsed hairy cell leukemia patient", Annals of Hematology, 81, 736–738.
   Google Scholar
• Zinzani, P.L., Ascani, S., Piccaluga, P.P., Bendandi, M., Pileri, S. and Tura, S. (2000) "Efficacy of rituximab in hairy cell leukemia treatment", Journal of Clinical Oncology, 18, 3875–3877.
   PubMed Web of Science ®Google Scholar
• Hoffman, M. and Auerbach, L. (2000) "Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine", British Journal of Haematology, 109, 900–901.
   PubMed Web of Science ®Google Scholar
• Hagberg, H. (1999) "Chimeric monoclonal anti-CD20 antibody (rituximab) — an effective treatment for a patient with relapsing hairy cell leukaemia", Medical Oncology, 16, 221–222.
   PubMed Web of Science ®Google Scholar
• Nieva, J., Bethel, K. and Saven, A. (2003) "Phase II study of rituximab in the treatment of cladribine-failed patients with hairy cell leukaemia", Blood, (in press).
   Google Scholar
• Kreitman, R.J., Wilson, W.H., White, J.D, Stetler-Stevenson, M., Jaffe, E.S., Giardina, S., et al. (2000) "Phase I trial of recombinant immunotoxin anti-Tac (Fv) PE38 (LMB-2) in patients with hematologic malignancies", Journal of Clinical Oncology, 18, 1622–1636.
   PubMed Web of Science ®Google Scholar